# A Clinical Trial of BGT-002 Tablets in Subjects With Nonalcoholic Steatohepatitis

> **NCT06491576** · PHASE1,PHASE2 · COMPLETED · sponsor: **Burgeon Therapeutics Co., Ltd.** · enrollment: 48 (actual)

## Conditions studied

- NASH

## Interventions

- **DRUG:** BGT-002
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06491576
- **Lead sponsor:** Burgeon Therapeutics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-21
- **Primary completion:** 2024-03-04
- **Final completion:** 2024-03-04
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2024-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06491576

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06491576, "A Clinical Trial of BGT-002 Tablets in Subjects With Nonalcoholic Steatohepatitis". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06491576. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*